Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-Transfected Dendritic Cell Vaccine in Glioblastoma
NCT00846456Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jan 2009
- Primary completion
- Feb 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of Autologous tumor stem cell mRNA-transfected dendritic cells in glioblastoma (GBM), sponsored by Oslo University Hospital. Started Jan 2009; status: completed.
02
Drugs
Autologous tumor stem cell mRNA-transfected dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00846456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846456.